Flu killed roughly 51,000 Americans in the 2023-2024 season. The vaccine that most of them received was grown in chicken eggs, a process invented in the 1940s, and it matched the circulating strain about 40-60% of the time in a decent year. Now there is a proposal to spend $500 million shoring up that same egg-based manufacturing capacity, framed as protecting domestic supply chains. The framing is not wrong. The conclusion is.
The core argument for old-platform investment is that egg-based production is proven, domestic, and does not depend on the cold-chain logistics that complicated early mRNA rollouts. That is a fair point. Supply chain resilience matters, and the 2020-2021 mRNA rollout exposed real distribution gaps. But "proven" is doing a lot of work in that sentence. Proven at what? Egg-based flu vaccines require manufacturers to predict the dominant strain roughly 6 months before flu season peaks. When they guess wrong, which happens regularly, efficacy drops below 20%. The 2014-2015 season hit 19%. That is not a supply chain problem. That is a fundamental limitation of the platform.
Speed Is the Only Metric That Matters in a Pandemic
mRNA flu vaccines can be redesigned in days once a new strain is sequenced. Egg-based production cannot compress that 6-month window without a complete infrastructure overhaul. Moderna's mRNA flu candidate showed 15-20% better efficacy against mismatched strains in Phase 3 trials. Pfizer's mRNA flu program is in late-stage trials now. Neither requires eggs, neither requires the same lead time, and both can pivot faster when a novel strain emerges.
The $500 million question is not really about flu. It is about what the US wants its pandemic response infrastructure to look like in 2035. Egg-based capacity takes years to build and decades to depreciate. Spending that money now is not just a procurement decision; it is a 20-year architectural commitment to a slower platform at exactly the moment when the faster one is proving itself at scale. The COVID mRNA vaccines reached 70% of US adults within 8 months of emergency authorization. That deployment speed is the benchmark every future platform gets measured against.
The Policy Context Makes This Worse
This investment debate lands in a specific moment. CDC removed flu from routine childhood vaccine recommendations in January 2026. Vaccination coverage data released March 27, 2026 already shows declines in flu vaccination among the youngest children. If the US is simultaneously pulling back on flu vaccine uptake and locking $500 million into legacy manufacturing, it is spending on supply for a demand it is actively suppressing. That is not a supply chain strategy. It is two contradictory policies running in parallel.
I hold a tension here I should name: mRNA manufacturing is not yet as geographically distributed as egg-based production, and rural access to mRNA cold-chain logistics remains a real gap. A hybrid approach, some investment in modernizing existing facilities while funding mRNA scale-up, is defensible. But $500 million allocated primarily to egg-based capacity is not a hybrid. It is a retreat dressed up as resilience.
HHS should redirect the majority of this funding toward domestic mRNA manufacturing capacity and cold-chain infrastructure in underserved regions. Keep a smaller reserve for egg-based production as a genuine backup, not the primary bet. The goal is a flu vaccine that works when the strain shifts unexpectedly, not one that is merely available. Those are different problems, and only one of them costs 51,000 lives a year when you get it wrong.
